Evidence map›Paper›PMID 41311410›Full record

ArticleActa pharmaceutica Sinica. B2025

Arsenic trioxide-based nanoparticles for enhanced chemotherapy by activating pyroptosis.

Shengmei Wang, Ding Ma, Minghua Yang, Ye Zhang, Shengfeng Wang, Wenhu Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  3. Article
  4. The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  5. Article
  6. Copper, cuproptosis, and cancer: biology concepts of a novel cell death.Apoptosis : an international journal on programmed cell death · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Selective CBPharmaceuticals (Basel, Switzerland) · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shengmei WangDepartment of Pharmacy, the third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Ding MaDepartment of Gastroenterology, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Minghua YangDepartment of Pediatrics, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Ye ZhangDepartment of Pediatrics, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Shengfeng WangDepartment of Pharmacy, the third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Wenhu ZhouXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy remains a primary treatment option for hepatocellular carcinoma (HCC), yet its clinical benefits are often unsatisfactory. Utilizing arsenic trioxide (ATO) as a model, this study elucidates the role of autophagy inhibition in modulating the cellular response to chemotherapy, shifting cell death from apoptosis to pyroptosis

Indexed as

Arsenic trioxideCell deathChemotherapyDrug deliveryHepatocellular carcinomaNanoparticlesTargetingTumor immunity

Identifiers

PMID41311410
PMCPMC12647999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.